As of March 17, 2024, Thailand had approximately 4.76 million confirmed COVID-19 cases. In that same period, there were 34,576 deaths from COVID-19 in the country.

Impact on the economy in Thailand The Thai economy was heavily impacted during the peak of the pandemic. Various restrictions were imposed in the country, resulting in businesses being temporarily interrupted or even permanently shut down. This resulted in a marked decrease in the gross domestic product (GDP) in 2020. One of the most impacted industries in Thailand was tourism. For months, Thailand had exercised regulations for visitors, such as quarantining, causing the tourism contribution to GDP to drop significantly.

Impact on the society in Thailand The COVID-19 pandemic also impacted the ways of life of Thai people. Apart from additional concerns for their health, Thai people had to adapt to changes in their daily lives. Some key changes include the increasing popularity of online shopping, cashless payments, online education, and even working from home. In January 2023, a survey conducted on online shopping behavior in Thailand suggested that the majority of Thais have shopped online more. Working from home also became the norm for many employees during the pandemic. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Thailand recorded 4736356 Coronavirus Cases since the epidemic began, according to the World Health Organization (WHO). In addition, Thailand reported 33989 Coronavirus Deaths. This dataset includes a chart with historical data for Thailand Coronavirus Cases.

In past 24 hours, Thailand, Asia had N/A new cases, N/A deaths and N/A recoveries.

As of 10th March 2023, the majority of third-dose vaccinated people against COVID-19 in Thailand were administered with Pfizer, amounting to approximately 17.9 million. This was followed by AstraZeneca and Moderna respectively.

As of 10th March 2023, the majority of second-dose vaccinated people against COVID-19 in Thailand were administered with AstraZeneca, amounting to approximately 28.7 million. This was followed by Pfizer and Sinopharm respectively.

This Project Tycho dataset includes a CSV file with COVID-19 data reported in THAILAND: 2019-12-30 - 2021-07-31. It contains counts of cases and deaths. Data for this Project Tycho dataset comes from: "COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University", "European Centre for Disease Prevention and Control Website", "World Health Organization COVID-19 Dashboard". The data have been pre-processed into the standard Project Tycho data format v1.1.

As of March 2022, about 20.3 percent of respondents stated that the Thai government should reduce cost of living during the COVID-19 pandemic in the country. Moreover, fast and convenient access to medical treatment was one of the suggestions for the government support during such time.

WHO: COVID-2019: Number of Patients: Death: New: Thailand data was reported at 0.000 Person in 24 Dec 2023. This stayed constant from the previous number of 0.000 Person for 23 Dec 2023. WHO: COVID-2019: Number of Patients: Death: New: Thailand data is updated daily, averaging 0.000 Person from Jan 2020 (Median) to 24 Dec 2023, with 1442 observations. The data reached an all-time high of 312.000 Person in 18 Aug 2021 and a record low of -60.000 Person in 22 Nov 2020. WHO: COVID-2019: Number of Patients: Death: New: Thailand data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Health Organization: Coronavirus Disease 2019 (COVID-2019): by Country and Region (Discontinued). Prior to 03 Feb 2020, data were generated.

WHO: COVID-2019: Number of Patients: Death: To-Date: Thailand data was reported at 34,514.000 Person in 24 Dec 2023. This stayed constant from the previous number of 34,514.000 Person for 23 Dec 2023. WHO: COVID-2019: Number of Patients: Death: To-Date: Thailand data is updated daily, averaging 21,729.000 Person from Jan 2020 (Median) to 24 Dec 2023, with 1442 observations. The data reached an all-time high of 34,514.000 Person in 24 Dec 2023 and a record low of 0.000 Person in 22 Nov 2020. WHO: COVID-2019: Number of Patients: Death: To-Date: Thailand data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Health Organization: Coronavirus Disease 2019 (COVID-2019): by Country and Region (Discontinued).

View daily updates and historical trends for Thailand Coronavirus Death Rate. Source: Johns Hopkins Center for Systems Science and Engineering. Track econ…

Thailand recorded 207479 Coronavirus Recovered since the epidemic began, according to the World Health Organization (WHO). In addition, Thailand reported 21260 Coronavirus Deaths. This dataset includes a chart with historical data for Thailand Coronavirus Recovered.

Covid fully vaccinated people per hundred people in Thailand, September, 2022 The most recent value is 74.6 Covid fully vaccinated people per hundred people as of September 2022, an increase compared to the previous value of 74.45 Covid fully vaccinated people per hundred people. Historically, the average for Thailand from March 2021 to September 2022 is 45.17 Covid fully vaccinated people per hundred people. The minimum of 0.04 Covid fully vaccinated people per hundred people was recorded in March 2021, while the maximum of 74.6 Covid fully vaccinated people per hundred people was reached in September 2022. | TheGlobalEconomy.com

Data set of the article "Stigmatizing attitudes toward COVID-19 among various Thai populations."

The number of COVID-19 vaccination doses administered in Thailand rose to 142635014 as of Jul 15 2023. This dataset includes a chart with historical data for Thailand Coronavirus COVID-19 Vaccination Total.

Additional file 2. Table S2: Rapid antigen test in 394 SARS-CoV-2 RT-PCR-negative cases. Characteristics of each SARS-CoV-2 RT-PCR-negative case (n=394) including gender, initial diagnosis, specimen type, Ct-value of RT-PCR (E, RdRp, N), RT-PCR result, Standard Q COVID-19 Ag test result, and time from symptom onset to laboratory test are demonstrated. Continuous data were presented in mean, standard deviation (SD), median, and range (min, max).

IntroductionThis study aimed to investigate factors associated with time-to-referral due to worsening symptoms in patients with laboratory-confirmed COVID-19 in southern Thailand. While underlying diseases have been evaluated to assess COVID-19 severity, the influence of vaccinations and treatments is also crucial.MethodsA cohort of 8,638 patients quarantined in home or community isolation with laboratory-confirmed COVID-19 was analyzed. Survival analysis and the Cox proportional hazard ratio were employed to assess factors influencing time-toreferral.ResultsAge ≥ 60 years, neurologic disorders, cardiovascular disease, and human immunodeficiency virus infection were identified as significant risk factors for severe COVID-19 referral. Patients who received full- or booster-dose vaccinations had a lower risk of experiencing severe symptoms compared to unvaccinated patients. Notably, individuals vaccinated during the Omicron-dominant period had a substantially lower time-to-referral than those unvaccinated during the Delta-dominant period. Moreover, patients vaccinated between 1 and 6 months prior to infection had a significantly lower risk of time-to-referral than the reference group.DiscussionThese findings demonstrate early intervention in high-risk COVID-19 patients and the importance of vaccination efficacy to reduce symptom severity. The study provides valuable insights for guiding future epidemic management strategies and optimising patient care during infectious disease outbreaks.

ObjectiveTo investigate clusters of students’ COVID-19 preventive behaviors and their associated factors.MethodsWe surveyed undergraduate students using an online questionnaire at a regional university in southern Thailand, between April and June 2022. Statistical analyses included latent class analysis and multinomial regression analysis.ResultsThree latent classes were identified: moderately consistent practitioner (7.5%), high compliance overall (48.9%), and good compliance with routine safeguards (43.6%). Females tended to have high compliance overall (RRR 2.46 95% CI 1.23–4.94), and higher academic performance was associated with high compliance overall and good routine safeguards. Perceived threats from COVID-19 were associated with good compliance with routine safeguards (RRR 4.21 95% CI 1.70–10.45). Benefits of actions and clear cues to action were associated with high overall compliance (RRR 5.24 95% CI 2.13–12.90). Students who perceived feasibility were more likely to be moderately consistent practitioners.ConclusionThe common clusters of the students’ preventive behaviors were high compliance overall and good compliance with routine preventions. Female, academic performance, perceived threats, and perceived benefits and cues to action were associated with compliance.

Estimates of R0 for COVID-19 in Thailand using exponential growth rate (EG) and maximum likelihood (MLE) methods with two different distributional assumptions (Log-Normal and Gamma) of serial interval.

The COVID-19 pandemic has had a significant impact on the tourism industry, especially in Thailand. Starting in April 2020, the Thai government banned international travel and all elephant tourist camps closed. A wide variety of management changes were implemented because of the lack of income from tourists. This study surveyed 30 camps that cared for >400 elephants in northern Thailand to obtain information on camp, elephant, and mahout management during the COVID-19 pandemic from April 2020 to 2022 compared to the year before. The survey consisted of questionnaires that interviewed elephant camp owners, managers, veterinarians, and mahouts, and captured information on changes in camp operations, including numbers of tourists, elephants and mahouts, elephant and mahout activities, and veterinary care. Results revealed significant changes in camp structure, elephant work activities and general care. Staff layoffs led to a decrease in the ratio of mahouts to elephants from 1:1 to 1:2. Elephant activities, distance walked, and amounts of food were reduced when compared to pre-COVID-19, while chain hours were increased due to reduced activity. Overall, the COVID-19 crisis altered elephant management significantly, potentially affecting animal welfare resulting from changes in nutrition, health, exercise, and numbers of mahouts. We hope to use these data to develop better management plans and guidelines for elephant camps in Thailand so they can cope with the current and potential imminent pandemics that result in decreased tourism income. A follow-up study will measure health and welfare markers in relation to COVID-19 induced changes to determine if any camps adapted management to still meet elephant health and welfare needs, and could serve as models for responding to future pandemics.

As of March 2023, approximately 48.9 million doses of Pfizer COVID-19 vaccine had been administered in Thailand. Other major vaccines included AstraZeneca with around 48.7 million doses administered, and Sinovac with around 26.6 million doses administered in the country.